Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987402 | 0.84 | — | — | |
| SCHEMBL22529052 | 0.84 | — | — | |
| SCHEMBL17440119 | 0.83 | CHRM1 (0.41) | CHRM1 | |
| SCHEMBL9930747 | 0.83 | CHRM1 (0.33) | CHRM1 | |
| SCHEMBL12099248 | 0.83 | CHRM1 (0.41) | CHRM1 | |
| SCHEMBL16668056 | 0.83 | CHRM1 (0.33) | CHRM1 | |
| SCHEMBL31734687 | 0.83 | CHRM1 (0.41) | CHRM1 | |
| SCHEMBL18048124 | 0.82 | SYK (0.38) | — | |
| SCHEMBL28518430 | 0.82 | SYK (0.38) | — | |
| SCHEMBL14332451 | 0.82 | SYK (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10155765-B2 | Carboxamide inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180051027-A1 | CARBOXAMIDE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2018-02-22 | — | — | US | disclosed |
| EP-3268367-A1 | CARBOXAMIDE INHIBITORS OF IRAK4 ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016144844-A1 | CARBOXAMIDE INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051027-A1 | CARBOXAMIDE INHIBITORS OF IRAK4 ACTIVITY | IRAK4, IRAK2, IRAK1 | CHRM1 4200/4885 |
| US-10155765-B2 | Carboxamide inhibitors of IRAK4 activity | IRAK4, IRAK2, IRAK1 | CHRM1 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.